PDS (PDSB) Climbs 7.46% on June 21

Equities Staff  |

PDS Biotechnology Corporation (NASDAQ: PDSB) shares are up 7.46%, or $0.25 per share, as on 11:54:49 est today. Since opening at $3.15, 180,483 shares of PDS have been traded today and the stock has moved between $3.67 and $3.46.  

This year the company has a YTD change of 58.64%.

PDS anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on PDS visit the company profile.

About PDS Biotechnology Corporation

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

To get more information on PDS Biotechnology Corporation and to follow the company's latest updates, you can visit the company's profile page here: PDS Biotechnology Corporation's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?

Market Movers

Sponsored Financial Content